AIDS Research and Human Retroviruses · 2012 · 10 citations · 48 references
Life SciencesImmunologyPharmacologyMolecular PharmacologyMolecular VirologyVirologyAntiviral AgentsAntiviral ImmunityAntiviral PharmacologyLipid RaftsLipid-protein InteractionsMembrane DomainsAcquired Immunodeficiency SyndromeLipid Raft EntryLipid Raft OrganizationLipid Raft StructureLipid Raft-dependent EntryLipid Raft-mediated EntryPathogen Entry Via RaftsVirus Entry At Membrane Microdomains
Development of an effective low-cost anti-acquired immunodeficiency syndrome (AIDS) drugs is needed for treatment of AIDS patients in developing countries. Host cell lipid raft microdomains, which are enriched with cholesterol, glycolipids, ceramide, and gangliosides, are important for human immunodeficiency virus type 1 (HIV-1) entry. Retinoid analogs have been shown to modulate ceramide levels in the cell membrane, while cholera toxin B subunit (CT-B) specifically binds to the ganglioside GM1. In this study, we found that the acyclic retinoid analogs geranylgeranoic acid (GGA) and NIK-333 as well as CT-B efficiently attenuate CXCR4-tropic, but not CCR5-tropic, HIV-1 vector infection. We also found that GGA and NIK-333 suppress CXCR4-tropic HIV-1 infection by attenuating CXCR4 expression. CT-B also attenuated CXCR4-tropic HIV-1 infection, but did not suppress CXCR4 expression. These results suggest a distinct role for lipid raft microdomains in CXCR4- and CCR5-tropic HIV-1 infections and illuminate novel agents for the development of AIDS therapy.
48
Membrane raft microdomains mediate lateral assemblies required for HIV‐1 infection
Santos Mañes, Gustavo del Real, Rosa Ana Lacalle et al. · EMBO Reports · 2000 · 355 citations · Full text
Britta Maurer, Leonid S. Metelitsa, Robert C. Seeger et al. · JNCI Journal of the National Cancer Institute · 1999 · 289 citations · Full text
Medicine, Oncology, Pharmacology +15